RSC Medicinal Chemistry · 2022 · 19 citations · 41 references
MedicineMedicinal ChemistryOncologyCarcinogenesisDrug DiscoveryMolecular OncologyCancer Cell SignalingCancer ProgressionOncogenic Signaling PathwaysTargeted Cancer TherapyEukaryotic Elongation FactorsKinase Signaling InhibitorsMolecular Target SelectionProtein Kinase InhibitorsTargeted Inhibitor DesignTriple-negative Breast Cancer Therapy
Eukaryotic elongation factor 2 kinase (eEF2K) has been shown to be an important molecular driver of tumorigenesis and validated as a potential novel molecular target in various solid cancers including triple negative breast cancer (TNBC).
41